Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/302% below fair value

$31.59−0.17 (-0.54%)

Close on Nov 13, 2026Market cap $1.89BP/E –Yield –

Agios Pharmaceuticals ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2019 it was -$308.18M.

Period	Period end	Value	Change
FY2019	Dec 31, 2019	-$308.18M	–
FY2018	Dec 31, 2018	-$355.31M	–
FY2017	Dec 31, 2017	-$314.36M	–

Parsed from the XBRL in Agios Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AGIO.

Revenue growth214.4% · median 29.9%

Gross margin93.8% · median 84.3%

Operating margin-297.7% · median 26.3%

Net margin-264.8% · median 35.3%

Advertisement
300 × 250

See a number that looks wrong?